Alkeus Pharmaceuticals, Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   ALK-001 on Stargardt Disease (TEASE)

   Primary completion pushed from Dec 2026 to Dec 2028

   Also in this update: Study completion pushed from Dec 2026 to Dec 2029

   Alkeus Pharmaceuticals, Inc.·Phase 2· NCT04239625· Registry history of NCT04239625 on ClinicalTrials.gov (opens the registry)

   Updated Sep 21, 2026

2. Notable

   TEASE · ALK-001 on Stargardt Disease

   Primary completion pushed from Jun 30, 2026 to Jun 30, 2028

   Also in this update: Trial status changed: Enrolling by Invitation → Active, Not Recruiting; Study completion pushed from Nov 30, 2026 to Nov 30, 2028

   Alkeus Pharmaceuticals, Inc.·Phase 2· NCT02402660· Registry history of NCT02402660 on ClinicalTrials.gov (opens the registry)

   Updated Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.